Clinical data | |
---|---|
Other names | VK-2809; MB07811 |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H32ClO5P |
Molar mass | 514.98 g·mol−1 |
VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis [1] [2] and is also being investigated for glycogen storage disease type Ia. [3]
Clinical data | |
---|---|
Other names | VK-2809; MB07811 |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H32ClO5P |
Molar mass | 514.98 g·mol−1 |
VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis [1] [2] and is also being investigated for glycogen storage disease type Ia. [3]